

Glutathione S-Transferases and Prevention of Cellular Free Radical Damage

BRIAN KETTERER *

Department of Oncology, University College Medical School, London W1P 8BT, UK

Accepted by Prof. V. Darley-Usmar

(Received 28 December 1997; In revised form 16 February 1998)

This paper describes the intervention of glutathione-dependent enzymes, in particular the glutathione S-transferases (GSTs), in both the detoxication of electrophilic decomposition products resulting from the attack of oxygen radicals on lipids and DNA; and the prevention of oxygen toxicity generated by redox cycling catecholamine derivatives. The continuing growth of our knowledge of the glutathione S-transferase polygene family is described in terms of the increase in members of known gene families, the discovery of new ones and our increasing knowledge of their activities towards endogenous substrates.

Keywords: Glutathione S-transferases, hydroxynonenal, base-propenals, catecholamines, oxygen radicals

INTRODUCTION

Herman Esterbauer made an invaluable contribution to our knowledge of the chemical effects of radical oxygen on lipids and nucleic acids and their biological consequences. In particular he had a leading role in the identification and chemical and biological characterization of the hydroxyalkenals, in particular 4-hydroxy-2,3-

trans-nonenal (HNE).^[1] He was kindly, unpretentious, intellectually rigorous, and attracted many distinguished collaborators. He was a scientist of the old tradition – a scholar and a gentleman. He is greatly missed.

His extensive work on toxic products of lipid peroxidation in particular HNE was ground breaking with respect to the importance of radical oxygen for the generation of endogenous toxins from cellular components.

This paper describes electrophiles resulting from oxygen radical attack on endogenous lipid^[2] and DNA^[3] and the generation of redox cycling metabolites of the catecholamine neurotransmitters and are believed to participate in the pathogenesis of Parkinson's disease and schizophrenia.^[4,5] It also gives an account of our developing knowledge of the contribution of GSTs to both the detoxication of the electrophilic products of radical damage and the prevention of the generation of oxygen radicals by redox cycling. New gene families of glutathione S-transferases (GSTs) continue to be discovered

* Tel.: +44 171 380 9309. Fax: +44 171 380 9499. E-mail: b.ketterer@ucl.ac.uk.

and knowledge of their biologically significant substrates, rather than model substrates taken from the laboratory shelf, is beginning to accumulate. To date there are 9 gene families and 16 gene products which, together, contribute to the detoxication of a wide spectrum of electrophiles including both those resulting from the metabolism of xenobiotics and those from the attack of radical oxygen on endogenous molecules.^[6]

Products of Radical Attack on Polyunsaturated Fatty Acyl Groups in Cellular Phospholipids

Hydroxyalkenals are end-products of the attack of radical oxygen on polyunsaturated fatty acyl groups in lipids. Hydroperoxy fatty acyl groups are formed initially and have several options. They may be detoxified directly by endoplasmic reticulum bound Se-dependent phospholipid hydroperoxide glutathione peroxidase (PHGPX).^[7] Alternatively free hydroperoxy fatty acids may be released into the aqueous milieu by the lyolytic enzymes appropriate for either phospholipids or triglycerides, according to which undergoes peroxidation,^[8] and then detoxified by both Se-dependent glutathione peroxidases (GPX) and appropriate glutathione S-transferases (GSTs).^[9,10] The relative contributions of each of these different means of detoxifying lipid hydroperoxides depend on which enzymes are present in the tissue under attack and at what concentration.^[7,9] Hydroperoxides that escape this initial detoxication, may either initiate further lipid peroxidation, or undergo oxidative decomposition to a wide range of compounds that include alkanes, alkenes and the electrophilic alkenals, hydroxyalkenals and hydroxydienals, from among which HNE is a major component.^[1,2]

Esterbauer and his colleagues showed that the biochemical properties of HNE were many and varied, and that according to whether exposure was in μM or nM amounts the result could be

either toxicological or patho-physiological. HNE may be inactivated by conjugation with GSH by the catalytic action of GSTs (see Table I) and, because of its normally high cellular concentration ($\sim 5 \text{ mM}$), GSH gives sustained protection against substantial quantities of HNE although persistent high concentrations bring about marked GSH depletion and toxicity ensues. For example cellular lipid etc. may become vulnerable to reactive oxygen species and macromolecular nucleophiles are exposed to electrophilic attack by HNE. In the case of proteins it reacts with the thiol of cysteine residues, the ϵ -amino group of lysine residues, and certain other residues including histidine, with the consequent potential to destroy or diminish the function of a number of enzymes and other proteins critical for cellular function.^[2,11] One example is its ability to inactivate GSH reductase,^[12] the function of which is to maintain suitable levels of reduced cellular GSH. As a result HNE, at appropriate concentrations, not only depletes GSH by HNE-GSH conjugate excretion, but also impairs its regeneration from glutathione disulphide.

Alkenals are also cytotoxic. For example acrolein, released by metabolism of the chemotherapeutic agent cyclophosphamide causes serious toxicity in the bladder epithelium, that can be mitigated by GSH analogues such as N-acetyl cysteine and the pharmaceutical agent sodium mercaptoethane sulphonate agent (Mesna). Cellular GSH and GST defences in the trilaminar bladder epithelium are apparently insufficient for the high level of intoxication they suffer during cyclophosphamide therapy.^[13] The longer chain alkenals produced in lipid peroxidation, such as nonenal, are also important toxins.

Ethene, one of the alkenes produced during lipid peroxidation is a potential hazard. Though not itself toxic, it becomes so, if metabolized by cytochrome P450^[14] to ethylene oxide, an electrophile and a substrate for GST.^[15,16]

For examples of electrophilic products of lipid peroxidation including the metabolism of ethene to ethylene oxide, see Figure 1.

TABLE 1 Activities of human GSTs towards products of lipid peroxidation and DNA peroxidation

Substrate	hGSTA1-1	hGSTA4-4	hGSTM1-1	hGSTM2-2	hGSTP1-1	hGSTT1-1 ^[39]	hGSTT2-2 ^[45]	hGSTZ1-1
	(in $\mu\text{mol min}^{-1} \text{mg}^{-1}$)							
Ethylene oxide						+ve ^[14]		
Acrolein	0.9 ^[38]	18 ^[47]	7.1 ^[38]		26.3 ^[38]			
Crotonaldehyde	< 0.1 ^[47]	7.5 ^[47]	< 0.1 ^[38]		1.6 ^[38]			
Hydroxypentenal		7.4 ^[47]						
Nonenal		205 ^[47]						
Hydroxynonenal	5.0 ^[45] 0.86 ^[48]	176 ^[39] 189 ^[47] 54 ^[48]	3.2 ^[38]		0.6 ^[38]		0.12 ^[45]	
Hydroxydecenal		159 ^[47]						
Hexa-2,4-dienal	0.09 ^[48]	0.46 ^[48]						
Cumene hydroperoxide	10 ^[44]	0.7 ^[47]	0.3 ^[38]		< 0.1 ^[38]	2.8 ^[39]	6.9 ^[45]	0.16 ^[6]
9-Hydroperoxy linoleic acid	1.6 ^[38]	0.4 ^[45]	nil ^[38]		0.4 ^[38]		9.7 ^{[46]*}	
Dilinoleoyl phosphatidyl-choline hydroperoxide	nil	0.4 ^[41]	nil		nil			
Adenine propenal	0.7 ^[44]		3.7 ^[44]		77 ^[44]			
Cytosine propenal	< 0.1 ^[44]		< 0.1 ^[44]		1.0 ^[44]			
Thymine propenal	< 0.1 ^[44]		1.0 ^[44]		8.7 ^[44]			
Uracil propenal	< 0.1 ^[44]		1.2 ^[44]		15 ^[44]			
Aminochrome	0.04 ^[25]	< 0.01 ^[25]	0.76 ^[25]	148 ^[25]	0.08 ^[25]	nil ^[25]		
Dopachrome	0.02 ^[25]	< 0.01 ^[25]	1.2 ^[25]	64 ^[25]	0.04 ^[25]	nil ^[25]		
Noradrenochrome	0.05 ^[25]	< 0.01 ^[25]	0.47 ^[25]	75 ^[25]	0.02 ^[25]	nil ^[25]		
Adrenochrome	0.004 ^[25]	< 0.01 ^[25]	0.98 ^[25]	0.63 ^[25]	0.02 ^[25]	nil ^[25]		

*The only available value for the activity of GSTT2-2 for hydroperoxylinoleic acid is from the rat. +ve indicates a result that is positive in a mutagenicity test, but has not been quantified. Spaces indicate that the substrate has not yet been tested.

Products of Radical Attack on DNA


The attack of radical oxygen on DNA is genotoxic involving both purine and pyrimidine bases and deoxyribose moieties. In the former case, one of the products is believed to be 5-hydroperoxymethyl uracil, which may be reduced by GPX and certain GSTs, to 5-hydroxymethyl uracil,^[17] a recognized promutagenic lesion in DNA exposed to oxygen radicals. In the latter case, attack on deoxyribose moieties, results in promutagenic strand breakage and the release of cytotoxic and genotoxic base propenals, that are conjugated by GST.^[3,18,19] For examples of these electrophilic products of oxygen radical attack on DNA see Figure 2.

HNE, a product of radical attack on lipids, is also a genotoxin. It is mutagenic in bacteria,^[20,21]

induces sister chromatid exchange, DNA fragmentation^[22,23] and gives 1,N²-etheno-deoxyguanosine adducts on reaction with DNA.^[24]


Redox Cycling Ortho-Quinone Metabolites of Catecholamine Neurotransmitters

Oxidative metabolism of catecholamines e.g. dopa, adrenaline and noradrenaline gives rise to orthoquinone derivatives that undergo cyclization and further metabolism to aminochrome, dopachrome, adrenochrome and noradrenochrome. These quinones are susceptible to one-electron reduction by enzymes such as NADPH cytochrome P450 reductase and NAD(P)H quinone oxido-reductase to give



*ethylene is metabolised to ethylene oxide which is a substrate for GSTs.

FIGURE 1 GST substrates derived from lipid peroxidation namely, the fatty acyl hydroperoxide 9-hydroperoxy-linoleic acid, the alkenals, acrolein and croton aldehyde the hydroxy-alkenal, 4-hydroxynonenal and the conversion of ethylene to ethylene oxide by the action of cytochrome P450.



*5-hydroperoxymethyl uracil has not been detected but is assumed to be the precursor of 5-hydroxymethyl uracil.

FIGURE 2 GST substrates derived from DNA peroxidation namely, 5-hydroperoxymethyl uracil the putative precursor of 5-hydroxymethyl uracil a stable product of DNA peroxidation and the base propenals, thymine propenal and adenine propenal.

semiquinone radicals that undergo rapid redox cycling, producing quantities of superoxide anion and the resultant toxic reactive oxygen species. Degeneration of the dopaminergic neurons in the substantia nigra as a consequence of the redox cycling of the dopamine derivative aminochrome, has been proposed to contribute to the etiology of Parkinson's Disease and it is suggested that a similar process in the mesolimbic system, may contribute to the development of schizophrenia. These orthoquinone derivatives are also substrates for GSTs which therefore compete with the redox cycling pathway preventing the formation of products of reactive oxygen. This reaction is shown in Figure 3.^[25]

The Glutathione S-Transferases

From present evidence, GSTs occur in the vast majority of living forms that are aerobic.^[26,27] They have similar overall structures, regardless of their phylogenetic origin. In man and many other organisms, they occur as polygene families, which co-operate to protect against a broad range of electrophilic toxins. These may be the products of either the metabolism (usually mixed function oxygenase dependent) of many of the xenobiotics




FIGURE 3 Competition by GST with the NADPH cytochrome P450 redox cycling pathway of aminochrome and other catecholamine derived ortho-quinones. The redox cycling pathway produces oxygen radicals in abundance, but GSTs compete with this pathway, produces unreactive GSH conjugates and are therefore potent anti-oxidants.

encountered in nature, or be produced endogenously as described above. Detoxication may be either by conjugation when the electrophilic centre is carbon or reduced when it is oxygen or nitrogen. In the former case stable conjugates result that are eliminated from the cell by a plasma membrane-bound GSH conjugate transporter^[28,29] and are subsequently metabolized, mostly in the kidney, to mercapturic acids and excreted in the urine.^[30]

The native enzymes are dimers. Each monomer has an active centre enclosed by two domains: one the G domain, is principally concerned with the binding and activation of GSH, while the other, the H domain, is concerned with the binding and orientation of the electrophilic substrate. Figure 4 shows ribbon diagrams of representatives of the alpha, mu, pi, theta and

sigma families. In each of these the G-domain is on the right and the H-domain on the left of the active site which is shown occupied by GSH conjugates, or in one case GSH sulphonate, with their GSH moieties bound deep in the interior of the active site.^[27]

At present six gene families are known in man: alpha, mu, pi, theta, kappa and zeta. A human sigma has yet to be reported, although one has been isolated from rat spleen.^[31] The nomenclature of the known human gene loci according to the accepted nomenclature^[32] are as follows. The alpha class comprises *hGST A1, A2, A3, A4* and *A5*; the mu class *hGST M1^A, M1^B, M1^O, M2, M3^A, M3^B,^[33]M4* and *M5*; the theta class *hGSTT1, T1^O* and *T2*. Only one locus is known so far in each of the pi, kappa and zeta classes, namely, *hGST P1^A, P1^B, P1^C,^[34-36] hGSTK1^[37]*




FIGURE 4 Ribbon diagrams of the three-dimensional structures of human(h) GSTA1, rat(r) GSTM1, hGSTP1, blowfly GSTT1 and squid GSTS1. The GSH domain is on the right hand side and the H domain on the left. The active sites of hGSTA1, rGSTM1, hGSTP1 and blowfly GSTT1 are occupied by S-benzylglutathione, (9S,10S)-9-(S-glutathionyl)-10-hydroxy-9,10-dihydrophenanthrene, S-hexylglutathione, glutathione sulphonate and 1-(S-glutathionyl)-2,4-dinitrobenzene, respectively.^[27]

and *hGSTZ1*.^[6] It is seen GSTs *M1*, *M3*, *P1* and *T1* have allelic forms. The active dimeric forms of the enzymes are either homodimers, or heterodimers composed of closely related monomers from the same gene family. A similar nomenclature has been devised for mouse and rat GSTs.^[38]

Knowledge of the spectrum of *hGST* isoenzyme expression in tissues is very important, but so far incomplete. More extensive information is often available for the more recently characterized isoenzymes, where information from quantitative immunochemistry is available. So far the general consensus is that the human liver expresses *hGSTs A1*, *A2*, *A4*, *M1*, *T1*, *T2*, *K1*, *Z1*; the lung GSTs, *A4*, *M1*, *M3*, *P1*, *T1* and *T2*; the erythrocytes GSTs *P1* and *T1*; the lymphocytes *GSTP1* and *M1*, but not *T1*; the colon and the kidney GSTs *A1*, *M1*, *P1* and *T1*; the skin GSTs *M1*, *M3*, and *P1*; the brain GSTs *M1*, *M3*, *P1*, *A4*, *T1* and *Z1* and the testis GSTs *M1*, *M3*, *P1*, *A1*, *A4*, and *T1*; the prostate GSTs *P1* and *T1*; the spleen, *GSTP1*; the small intestine, *GSTT1*; the pancreas *GSTT1*; and the muscle GSTs *M1*, *M2*, *P1*, *A4*, *T1* and *Z1*.^[6,38-40] It is important to note that the recently characterised *hGSTA4-A4*, shown in Table I to have very high activity with HNE (and in addition activity with peroxidized phospholipid) is found in human liver, lung, brain, testis, muscle, small intestine, pancreas, bladder and in addition, retina, cornea, iris and ciliary body of the eye. It is very widely expressed.^[41,42] The tissue distribution of *GSTT2* in man is largely unknown, but studies in the rat record a broad distribution, which in order of tissue content is: liver, testis, adrenal, kidney, lung, brain, skeletal muscle, heart, small intestine and spleen.^[43] Tissue GST distribution requires much more investigation and involve all tissues possible. Account should be taken of inter-individual variation by sampling numbers of donors and expressing results statistically and it will be seen below that racial variation should also be considered.

Tables I and II illustrate the broad overlapping specificities of the human GSTs towards some

endogenous and exogenous substrates. Some of the exogenous substrates occur in Nature or are pollutants arising from modern industrial life, while others are laboratory chemicals.

In Tables I and II, the reactions that are catalyzed are classified as follows: CDNB, MS and CH_2Cl_2 are examples of nucleophilic displacement, BPDE, AFBO and ethylene oxide of attack of GSH on strained oxirane rings, EA, acrolein, crotonaldehyde, nonenal, HNE, hydroxydecenal, hydroxypentanal base propenals and aminochrome of Michael addition, Δ^5 AD, of GSH-dependent isomerism and CuOOH, linoleoyl hydroperoxide and dilinoleoyl phosphatidyl hydroperoxides of GSH dependent reduction. It is seen that the range in activities spans four orders of magnitude according to the substrate and that most substrates are utilized at different rates by more than one enzyme. For example, the best enzyme for CDNB is *hGSTM2-2*; for BPDE and AFBO, *hGSTM1-1*; for MS, *hGST2-2*; for CH_2Cl_2 , *hGSTT1-1*; for EA, either *hGSTA4-4* or *hGSTP1-1*; for Δ^5 AD, *hGSTA1-1* and for CuOOH, *hGSTA2-2* and *hGSTT2-2*. The best enzyme for many endogenous substrates derived from lipid peroxidation is *hGSTA4-4*; but there are exceptions: for example fatty acyl hydroperoxides are best detoxified by *hGSTT2-2* and the limited information available so far indicates that *GSTT1-1* is best for ethylene oxide. Present results from DNA peroxidation show *hGSTP1-1* to be the most effective enzyme with base propenals. With respect to the redox cycling catecholamine derivatives, *hGSTM2* is by far the best enzyme. However since neither substrates nor enzymes have been exhaustively tested, these data are incomplete.^[32]

Genetic Polymorphism in the Glutathione Transferases

As seen above GSTs *M1*, *M3*, *P1*, and *T1* exhibit genetic polymorphism. The substrate spectrum of *hGSTM3* has been little studied, for example it

TABLE II Activities of human GST isoenzymes towards some exogenous substrates

Isoenzyme	CDNB	BPDE	exo-AFBO	endo-AFBO	MS (in $\mu\text{mol mg}^{-1} \text{min}^{-1}$)	CH ₂ Cl ₂	EA	Δ^5 AD	CuOOH
hGSTA1-1	82.0	0.038 ^[49]	0.009 ^[50]	< 0.01 ^[50]			0.1	4.0	3.1
hGSTA2-2	80.0		0.01 ^[50]	< 0.01 ^[50]			0.1		10.4
hGSTA4-4	12.5						2.8		0.6
hGSTM1-1	190.0	0.57 ^[49]	0.6 ^[50]	1.4 ^[50]			0.1	0.12	0.3
hGSTM2-2	276.0						0.2		0.1
hGSTM3-3	15.2						0.2		0.05
hGSTM4-4	1.4						0.1	nil	
hGSTP1-1	103.0	0.83 ^[49]	0.06 ^[50]	< 0.06 ^[50]			1.22		0.03
hGSTT1-1	nil				nil	0.4 ^[39]	nil		2.8 ^[39]
hGSTT2-2	nil				0.3 ^[45]		0.3 ^[45]		6.9 ^[45]
hGSTZ1-1	nil						0.05 ^[6]		0.16 ^[6]

CDNB, 1-chloro-2,4-dinitrobenzene; BPDE, benzo(a)pyrene-7,8-diol-9,10-oxide; AFBO, aflatoxin B₁-8,9-oxide; MS, 1-menaphthyl sulfate; CH₂Cl₂, methylene chloride; EA, ethacrynic acid; Δ^5 AD, Δ^5 androstene-3,17-dione; CuOOH, cumene hydroperoxide. Spaces indicate that the substrate has not been tested with the isoenzyme in question. All data are adapted from^[38] except those otherwise marked.

is not known whether or not it utilizes products of reactive oxygen as substrates. *GSTM1* has three alleles, namely *M1*A*, *M1*B* and *M1*0*. Whereas *GSTM1*A* and *M1*B* differ by only one base in exon 7, without apparent effect on the activity of the enzyme phenotype, *GSTM1*0* represents a gene deletion and when homozygous, produces a null phenotype. *GSTP1* has four polymorphisms *hGSTP1*A*, *hGSTP1*B*, *hGSTP1*C* and *hGSTP1*D* as a result of variants at codons 104 and 113. At codon 104 *hGSTP1*A* codes for Ile and *hGSTP1*B* or Val. In the case of *hGSTP1*C* and *hGSTP1*D* both codons are involved.^[36] These two codons are at the substrate binding site and are expected to affect activity. In the theta family *GSTT1*, like *GSTM1*, has a null allele that also results from a large deletion and gives a null phenotype when homozygous. Data relating these polymorphisms to susceptibility to disease are accumulating; but the causal connection between the substrates utilized by a particular gene product and the diseases associated with the polymorphism of this gene is not always clear. Perhaps one exception is the association of *GSTM1* null with susceptibility to diseases such as smoking-dependent lung or bladder cancer. Benzo(a) pyrene is a major component of tobacco smoke and its carcinogenic metabolite, BPDE, is a good substrate for *GSTM1* (see Table II).^[51,52]

With reference to endogenous substrates, Table II shows that *hGSTM1* is not a particularly powerful enzyme for any of the substrates resulting from radical attack on either lipid or DNA, and the effect of its polymorphism is probably small in this respect. It may however be important in diseases resulting from adrenochrome recycling. Adrenochrome, unlike other catecholamine derivatives is a better substrate for *GSTM1* than *GSTM2*. The polymorphism of *hGSTP1-1* on the other hand, might be important with respect to detoxication of the base pro-penals, particularly since *GSTP1* is so widely distributed, but at present we know nothing about the relative activities of the three allelic forms for these substrates. In the case of *GSTT1* null individuals, ethylene oxide would not be effectively detoxified and it has been proposed that this might explain the higher base-line sister chromatid exchange associated with the null phenotype.^[53] The most remarkable enzyme with respect to lipid derived substrates is *GSTA4-4* which may occur as several isoenzymes. The view at the moment is that these are not allelic forms.

The Frequency of GST Polymorphisms

The frequencies of polymorphisms vary with the GST and the racial type. Differences in

distribution of hGSTM1 null and hGSTT1 null phenotypes are often very significant. Thus in decreasing order the incidence of GSTM1 null is: Malays 64%; Chinese 63%; US Caucasians 50%; Indians 32% and African Americans 20%. In the case of GSTT1 null the incidence is: Chinese 64%; Koreans 60%; Malays 38%; U.S. Caucasians 24%; African Americans 22%; Indians 16% and Mexican Americans 9%.^[51,54,55] The frequency of the polymorphic forms of hGSTP1 is not known.^[36]

Induction and Chemoprotection

GSTs are inducible and their induction reduces susceptibility to reactive oxygen derived endogenous substrates and is therefore chemoprotective. Most of our information concerning induction and its potential for chemoprotection depends on work with experimental animals. In the rat the inducer 1,2-dithiole-3-thione and its derivative oltipraz induces hepatic alpha and mu enzymes, including rGSTA4-4, the orthologue of hGST4-4, and is also able strikingly to increase the expression of rGSTP1-1 and rGSTA5-5 from very low basal levels. Such induction has been recorded in several other tissues and is assumed to be a general effect.^[56] In the case of aflatoxin B₁ (AFB)-induced hepatocarcinogenesis in the rat, oltipraz has been shown to be a very effective chemoprotector,^[57] by virtue of its induction of rGSTA5-5, the most effective enzyme by far, for the detoxication of the carcinogenic metabolite AFB-*exo*-8,9-oxide.^[50] In studies on both rats and mice, the plant product curcumin has also been shown to induce hepatic GSTs.^[58,59] Relevant to substrates produced by oxidative stress is the observation that curcumin protects against HNE-induced cataract in the rat lens. In these experiments rGST4-4 in the lens is powerful in the detoxication of HNE and may also intervene at earlier stages of oxidative damage by detoxifying fatty acyl hydroperoxide-containing lipids.^[59] This work showing that curcumin is anti-cataractogenic is comparable to the ground breaking experiments of Kensler *et al.*^[57]

rGSTA4-4 is also selectively induced by iron-induced lipid peroxidation. It is suggested that the agent responsible for the induction is HNE, one of its principal substrates.^[60]

Metabolism of HNE

There are three pathways of metabolism of HNE as follows: (1) as already, described, GST-dependent GSH conjugation; (2) oxidation of the aldehyde group by aldehyde dehydrogenase to give 4-hydroxy-2 nonenoic acid (HNA) and (3) reduction of the aldehyde by alcohol dehydrogenase to give 1,4-dihydroxy-2-nonene (DHN).^[61-63] In studies on isolated rat hepatocytes, only one of these potential reactions appears to occur to each substrate molecule. That is, the products are either HNE GSH, HNA or DHN, HNE GSH being the major product and increasingly so with time, due to HNE induction of rGSTA4-4.^[62] However HNE could be both GSH conjugated and, in addition, have its aldehyde group either oxidized or reduced and it is interesting that this does not happen in these isolated hepatocytes. However when whole animals were given HNE and the urinary mercapturic acids analysed, four were identified namely, hydroxynonenal mercapturic acid (HNE MA), HNA MA, HNA lactone MA, and DHN MA. It is shown that HNE MA (and presumably HNE-GSH) are not substrates for the dehydrogenases and cannot give rise to either HNA MA or DHN MA.^[64] It would appear that *in vivo* in the rat, oxidation and reduction of the aldehyde group of HNE are essential initial reactions and that the products HNA and DNH are both substrates for GST. If this is true it is now necessary to determine the enzyme utilisation and kinetics for these new substrates, both the GSH conjugates and the mercapturic acid derivatives. It is clear that in the rat *in vivo* GSH conjugation is essential for excretion of HNE. These differences in behaviour between hepatocyte cultures and the whole animal are important and require evaluation.

CONCLUSION

This article, as explained in the Introduction, has arisen out of the work of Herman Esterbauer on lipid peroxidation and the identification of HNE, a major product of this process and a powerful electrophile. Its topic is principally the detoxication by GSTs of a range of endogenous substrates resulting, not only from the oxygen radical attack on polyunsaturated fatty acyl derivatives and DNA but, in addition, from redox cycling catecholamine derivatives. It is now established that the GST polygene family has indeed the potential to provide a large umbrella of protection against endogenous substrates resulting from oxygen toxicity, whereas in the past this was largely notional. There are enzymes that catalyse these detoxications with very high activities. For example the catalytic activity of hGSTA4-4 for alkenals and hydroxy alkenals may be as high as 205 and 189 $\mu\text{mol}/\text{min}/\text{mg}$ respectively; of hGST P1-1 for base propenals, as high as 77 $\mu\text{g}/\text{min}/\text{mg}$; of hGSTM2 for aminochrome, 148 $\mu\text{g}/\text{min}/\text{mg}$ and of hGSTT2 for 9-hydroperoxylinoleic acid, 10 $\mu\text{g}/\text{min}/\text{mg}$. Compared with carcinogenic electrophiles such as BPDE which hGSTs P1-1 and M1-1 detoxify at rates of 0.8 and 0.6 $\mu\text{g}/\text{mg}/\text{min}$ respectively the above rates of detoxication of endogenous substrates are high indeed (Tables I and II). An important advance in our knowledge in this area would be the acquisition of data enabling quantitation of the tissue distribution of these enzymes, since this would enable the contribution of each tissue to the detoxication of a selected substrate to be computed.

In view of the presence of several enzymes with the capacity to detoxify HNE, it is interesting to learn that its basal level in plasma is about 0.3 μM ^[65] implying that low levels of reactive oxygen species are a normal feature of life. To confirm the power of the enzymes that detoxify HNE, it has been demonstrated that administration of up to 500-fold excess of HNE is necessary to affect the steady-state concentration in plasma.^[66] The maintenance of these low levels

of HNE seem to be important to provide a background against which small increments are able to carry out what appear to be physiological functions of HNE such as neutrophil chemotaxis^[67] associated with activation of phosphoinositide-specific phospholipase C,^[68] which has been studied in rats and humans: and also the stimulation of HeLa cell growth.^[69] This area is naturally of considerable interest and could be pursued much further, but is not the subject of this review.

Perhaps one could conclude by mentioning the possible manipulation of hGSTA4-4 to advance clinical medicine. It has been pointed out that hGSTA4-4 has substantial activity towards many of the toxic products of lipid peroxidation (Table I). This enzyme is present in a large range of normal tissues, but probably not in tumour cells (such as the hamster ovary cells below). If it could be induced, it might provide normal tissue with useful protection against anti-cancer cytotoxic drugs, producing reactive oxygen species. This proposition has not yet been tested, but Chinese hamster ovary cells, apparently lacking GSTA4-4, have been transfected with mGST4-4 and challenged with adriamycin. Compared with controls the mGST4-4-transfected cells have a two-fold higher resistance to adriamycin, associated with 40% less membrane peroxidation,^[70] which is not generally appreciated. This indicates that adriamycin toxicity is partially mediated by lipid peroxidation which is not generally appreciated. The induction of hGST4-4 in cancer patients about to undergo radiotherapy, where oxygen radicals are the principal toxins, might also be efficacious. This could be tested without delay since there is already a very powerful chemoprotective agent, namely oltipraz, that is licensed for clinical use.^[56]

References

- [1] A. Benedetti, M. Comporti and H. Esterbauer (1980). Identification of 4-hydroxynonenal as a cytotoxic product originating from the peroxidation of liver microsomal lipids. *Biochimica et Biophysica Acta*, **620**, 281.

- [2] H. Esterbauer, R.J. Schaur and H. Zollner (1991). Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. *Free Radical Biology and Medicine*, **11**, 81–128.
- [3] M.F. Janicek, W.A. Haseltine and W.D. Henner (1985). Malondialdehyde precursors in gamma-irradiated DNA, deoxynucleotides and deoxynucleosides. *Nucleic Acids Research*, **13**, 9011–9029.
- [4] J. Segura-Aguilar, S. Baez, M. Widersten, C.J. Welch and B. Mannervik (1997). Human class Mu glutathione transferases, in particular isoenzyme M2-2, catalyze detoxication of the dopamine metabolite aminochrome. *Journal of Biological Chemistry*, **272**, 5727–5731.
- [5] S. Baez, J. Segura-Aguilar, M. Widersten, A.-S. Johansson and B. Mannervik (1997). Glutathione transferases catalyze the detoxication of oxidized metabolites (*o*-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. *Biochemical Journal*, **324**, 25–28.
- [6] P.G. Board, R. Baker, G. Chelvanayagam and L. Jermini (1997). Identification and characterization of the zeta class of glutathione transferases in a range of species from plants to humans. *Biochemical Journal*, **328**, 929–935.
- [7] A. Roveri, A. Casasco, M. Maiorino, P. Dalan, A. Calligaro and F. Ursini (1992). Phospholipid hydroperoxide glutathione peroxidase of rat testis. *Journal of Biological Chemistry*, **267**, 6142–6146.
- [8] A. Sevanian, S.F. Muakkassah-Kelly and S. Montestruque (1983). The influence of phospholipase A2 and glutathione peroxidase on the elimination of membrane lipid peroxides. *Arch. Biochem. Biophys.*, **223**, 441–452.
- [9] R.A. Lawrence and R.F. Burk (1978). Species, tissue and subcellular distribution of non Se-dependent glutathione peroxidase activity. *Journal of Nutrition*, **108**, 211–215.
- [10] B. Ketterer and B. Coles (1991). Glutathione transferases and products of reactive oxygen. In *Oxidative Stress* (ed. H. Sies). Academic Press, London, pp. 117–194.
- [11] H. Esterbauer (1993). Cytotoxicity and genotoxicity of lipid-oxidation products. *American Journal of Clinical Nutrition*, **57**, 779S–786S.
- [12] D.L. Vander Jagt, L.A. Hunsaker, T.J. Vander Jagt, M.S. Gomez, D.M. Gonzales, L.M. Deck and R.E. Royer (1997). Inactivation of glutathione reductase by 4-hydroxynonenal and other endogenous aldehydes. *Biochemical Pharmacology*, **53**, 1133–1140.
- [13] N. Brock, J. Pohl and J. Stekar (1981). Detoxification of urotoxic oxazaphosphorines by sulphhydryl compounds. *Journal of Cancer and Clinical Oncology*, **100**, 311–320.
- [14] G.A. Csandy, R.J. Laib and J.G. Filser (1995). Metabolic transformation of halogenated and other alkenes – a theoretical approach. Estimation of metabolic reactivities for *in vivo* conditions. *Toxicology Letters*, **75**, 217–223.
- [15] S. Pemble, K.R. Schroeder, S.R. Spencer, D.J. Meyer, E. Hallier, H.M. Bolt, B. Ketterer and J.B. Taylor (1994). Human glutathione S-transferase Theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. *Biochemical Journal*, **300**, 271–276.
- [16] J.G. Filser and H.M. Bolt (1983). Exhalation of ethylene oxide by rats on exposure to ethylene. *Mutation Research*, **120**, 57–60.
- [17] B.N. Ames and R.L. Saul (1986). Cancer, aging and oxidative DNA damage. In *Theories of Carcinogenesis* (ed. O.H. Iversen). Hemisphere Publishing Corporation, New York, pp. 1–34.
- [18] L. Giloni, M. Takeshita, F. Johnson, C. Iden and A.P. Grollman (1981). Bleomycin-induced strand-scission of DNA: mechanism of deoxyribose cleavage. *Journal of Biological Chemistry*, **256**, 8608–8615.
- [19] A.P. Grollman, M. Takeshita, K.M.R. Pillai and F. Johnson (1985). Origin and cytotoxic properties of base propenals derived from DNA. *Cancer Research*, **45**, 1127–1131.
- [20] L.J. Marnett, H.K. Hurd, M.C. Hollstein, D.E. Levin, H. Esterbauer and B.N. Ames (1985). Naturally occurring carbonyl compounds are mutagens in Salmonella tester strain TA104. *Mutation Research*, **148**, 25–34.
- [21] M. Benamira and L.J. Marnett (1992). The lipid peroxidation product 4-hydroxynonenal is a potent inducer of the SOS response. *Mutation Research*, **293**, 1–10.
- [22] G. Brambilla, L. Sciaba, P. Faggin, A. Maura, U.M. Marinari, M. Ferro and H. Esterbauer (1986). Cytotoxicity, DNA fragmentation and sister-chromatid exchange in Chinese hamster ovary cells exposed to the lipid peroxidation product 4-hydroxynonenal and homologous aldehydes. *Mutation Research*, **171**, 169–176.
- [23] I. Emerit, S.H. Khan and H. Esterbauer (1991). Hydroxynonenal, a component of clastogenic factors? *Free Radical Biology and Medicine*, **10**, 371–377.
- [24] R.S. Sodum and F.-L. Chung (1988). 1,N²-ethenodeoxyguanosine as a potential marker for DNA adduct formation by *trans*-4-hydroxy-2-nonenal. *Cancer Research*, **48**, 320–323.
- [25] S. Baez, J. Segura-Aguilar, M. Widersten, A.-S. Johansson and B. Mannervik (1997). Glutathione transferases catalyze the detoxication of oxidized metabolites (*o*-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. *Biochemical Journal*, **324**, 25–28.
- [26] S.E. Pemble and J.B. Taylor (1992). An evolutionary perspective on glutathione transferases inferred from class-theta glutathione transferase cDNA sequences. *Biochemical Journal*, **287**, 957–963.
- [27] R.N. Armstrong (1997). Structure, catalytic mechanism, and evolution of the glutathione transferases. *Chemical Research in Toxicology*, **10**, 2–18.
- [28] T. Ishikawa, H. Esterbauer and H. Sies (1986). Role of cardiac glutathione transferase and of the glutathione S-conjugate export system in biotransformation of 4-hydroxynonenal in the Heart. *Journal of Biological Chemistry*, **261**, 1576–1581.
- [29] T. Ishikawa (1993). The ATP-dependent glutathione S-conjugate export pump. *TIBS* **5**, 164–166.
- [30] L.F. Chasseaud (1979). The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. *Advances in Cancer Research*, **29**, 175–274.
- [31] D.J. Meyer and M. Thomas (1995). Characterisation of rat spleen prostaglandin H D-isomerase as a sigma class GSH transferase. *Biochemical Journal*, **311**, 739–742.
- [32] B. Mannervik, Y.C. Awasthi, P.G. Board, J.D. Hayes, C. Di Ilio, B. Ketterer, I. Listowsky, R. Morgenstern, M. Muramatsu, W.R. Pearson, C.B. Pickett, K. Sato, M. Widersten and C.R. Wolf (1992). Nomenclature for human glutathione transferases. *Biochemical Journal*, **282**, 305–306.
- [33] A. Inskip, J. Elexperu-Camiruaga, N. Buxton, P.S. Dias, J. MacIntosh, D. Campbell, P.W. Jones, L. Yengi, J.A. Talbot, R.C. Strange and A.A. Fryer (1995). Identification

- of polymorphism at the glutathione-S-transferase, *GSTM3* Locus: evidence for linkage with *GSTM1**A. *Biochemical Journal*, **312**, 713–716.
- [34] L.W. Harries, M.J. Stubbins, D. Forman, G.C.W. Howard and C.R. Wolf (1997). Identification of genetic polymorphisms at the glutathione S-transferase II locus and association with susceptibility to bladder, testicular and prostate cancer. *Carcinogenesis*, **18**, 641–644.
- [35] F. Ali-Osman, O. Akande, G. Antoun, J.-X. Mao and J. Buolamwini (1997). Molecular cloning, characterization and expression in *Escherichia coli* of full-length cDNAs of three human glutathione S-transferase pi gene variants. *Journal of Biological Chemistry*, **272**, 10004–10012.
- [36] G. Tang, B. Coles and F. Kadlubar (1997). Personal Communication.
- [37] S.E. Pemble, A.F. Wardle and J.B. Taylor (1996). Glutathione S-transferase class Kappa: characterization by the cloning of rat mitochondrial GST and identification of a human homologue. *Biochemical Journal*, **319**, 749–754.
- [38] J.D. Hayes and D.J. Pulford (1995). The Glutathione S-transferase supergene family: Regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. *Critical Reviews in Biochemistry and Molecular Biology*, **30**, 445–600.
- [39] P.J. Sherratt, D.J. Pulford, D.J. Harrison, T. Green and J.D. Hayes (1997). Evidence that human class Theta glutathione S-transferase T1-1 can catalyse the activation of dichloromethane, a liver and lung carcinogen in the mouse. *Biochemical Journal*, **326**, 837–846.
- [40] E. Juronen, G. Tasa, M. Uuskula, M. Pooga and A.-V. Mikelsaar (1996). Purification, characterization and tissue distribution of human class theta glutathione S-transferase T1-1. *Biochemistry and Molecular Biology International*, **39**, 21–29.
- [41] S.S. Singhal, P. Zimniak, R. Sharma, S.K. Srivastava, S. Awasthi and Y.C. Awasthi (1994). A novel glutathione S-transferase isozyme similar to GST 8-8 of rat and mGSTA4-4 (GST5.7) of mouse is selectively expressed in human tissues. *Biochimica et Biophysica Acta*, **1204**, 279–286.
- [42] S.S. Singhal, S. Awasthi, S.K. Srivastava, P. Zimniak, N.H. Ansari and Y.C. Awasthi (1995). Novel human ocular glutathione S-transferases with high activity toward 4-hydroxynonenal. *Investigative Ophthalmology and Visual Science*, **36**, 142–150.
- [43] A. Hiratsuka, N. Sebata, K. Kawashima, H. Okuda, K. Ogura, T. Watabe, K. Satoh, I. Hatayama, S. Tsuchida, T. Ishikawa and K. Sato (1990). A new class of rat glutathione S-transferase Yrs-Yrs inactivating reactive sulfate esters as metabolites of carcinogenic arylmethanols. *Journal of Biological Chemistry*, **265**, 11973–11981.
- [44] K. Berhane, M. Widersten, Å. Engström, J.W. Kozarich and B. Mannervik (1994). Detoxication of base propenals and other α,β -unsaturated aldehyde products of radical reactions and lipid peroxidation by human glutathione transferases. *Proceedings of the National Academy of Science of the USA*, **91**, 1480–1484.
- [45] K.-L. Tan and P.G. Board (1996). Purification and characterization of a recombinant human Theta-class glutathione transferase (GSTT2-2). *Biochemical Journal*, **315**, 727–732.
- [46] A. Hiratsuka, T. Okada, T. Nishiyama, M. Fujikawa, K. Ogura, H. Okuda, T. Watabe and T. Watabe (1994). Novel theta class glutathione S-transferases Yrs-Yrs' and Yrs'-Yrs' in rat liver cytosol: their potent activity toward 5-sulfoxymethylchrysene, a reactive metabolite of the carcinogen 5-hydroxymethylchrysene. *Biochemical Biophysical Research Communications*, **202**, 278–284.
- [47] I. Hubatsch, M. Ridderström and B. Mannervik (1998). Human glutathione transferase A4-4: an Alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation. *Biochemical Journal*, **330**, 175–179.
- [48] P.G. Board (1998). Identification of cDNAs encoding two human alpha class glutathione transferases (GSTA3 and GSTA4) and the heterologous expression of GSTA4-4. *Biochemical Journal* (in press).
- [49] I.G.C. Robertson, C. Guthenberg, B. Mannervik and B. Jernström (1986). Differences in stereoselectivity and catalytic efficiency of three human glutathione transferases in the conjugation of glutathione with 7 β ,8 α -Dihydroxy-9 α ,10 α -oxy-7,8,9,10-tetrahydrobenzo(a)pyrene. *Cancer Research*, **46**, 2220–2224.
- [50] K.D. Raney, D.J. Meyer, B. Ketterer, T.M. Harris and F.P. Guengerich (1992). Glutathione conjugation of Aflatoxin B₁ *exo*- and *endo*-epoxides by rat and human glutathione S-transferases. *Chem. Res. Toxicol.*, **5**, 470–478.
- [51] R.C. Strange and A.A. Fryer (1997). The glutathione S-transferases: influences of polymorphism on susceptibility to cancer in *Metabolic Polymorphism and Cancer* (eds. P. Boffetta, N. Caporaso, J. Cuzick, M. Lang and P. Venneis), IARC Publications, Lyon.
- [52] B. Ketterer (1998, in press). Glutathione S-transferase polymorphism and susceptibility to cancer in *Medical and Workplace Applications of Biomarkers* (eds. M.L. Mendelsohn, L.C. Mohr and J.P. Peeters). Joseph Henry Press, National Academy of Sciences, Washington, DC.
- [53] J.K. Wiencke, S. Pemble, B. Ketterer and K.T. Kelsey (1995). Gene deletion of glutathione S-transferase theta: correlation with induced genetic damage and potential role in endogenous mutagenesis. *Cancer Epidemiology Biomarkers & Prevention*, **4**, 253–259.
- [54] E.J.D. Lee, J.Y.Y. Wong, P.N. Yeoh and N.H. Gong (1995). Glutathione S transferase- θ (GSTT1) genetic polymorphism among Chinese, Malays and Indians in Singapore. *Pharmacogenetics*, **5**, 332–334.
- [55] H.H. Nelson, J.K. Wiencke, D.C. Christiani, T.J. Cheng, Z.-F. Zuo, B.S. Schwartz, B.-K. Lee, M.R. Spitz, M. Wang, X. Xu and K.T. Kelsey (1995). Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S-transferase theta. *Carcinogenesis*, **16**, 1243–1245.
- [56] D.J. Meyer, J.M. Harris, K.S. Gilmore, B. Coles, T.W. Kensler and B. Ketterer (1993). Quantitation of tissue and sex specific induction of rat glutathione transferase subunits by dietary 1,2-dithiole-3-thiones. *Carcinogenesis*, **14**, 567–572.
- [57] T.W. Kensler, P.A. Egner, P.M. Dolan, J.D. Groopman and B.D. Roebuck (1987). Mechanism of protection against aflatoxin tumorigenicity in rats fed 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) and related 1,2-dithiole-3-thiones and 1,2-dithiole-3-ones. *Cancer Research*, **47**, 4271–4277.
- [58] M. Susan and M.N.A. Rao (1992). Induction of glutathione S-transferase activity by curcumin in mice. *Drug Research*, **42**, 962–964.
- [59] S. Awasthi, S.K. Srivastava, J.T. Piper, S.S. Singhal, M. Chaubey and Y.C. Awasthi (1996). Curcumin protects against 4-hydroxy-2-*trans*-nonenal-induced cataract formation in rat lenses. *American Journal of Clinical Nutrition*, **64**, 761–766.

- [60] M.F. Khan, S.K. Srivastava, S.S. Singhal, M. Chaubey, S. Awasthi, D.R. Petersen, G.A.S. Ansari and Y.C. Awasthi (1995). Iron-induced lipid peroxidation in rat liver is accompanied by preferential induction of glutathione S-transferase 8-8 isozyme. *Toxicology and Applied Pharmacology*, **131**, 63–72.
- [61] W.G. Siems, T. Grune, B. Beierl, H. Zollner and H. Esterbauer (1992). The metabolism of 4-hydroxynonenal, a lipid peroxidation product, is dependent on tumor age in Ehrlich mouse ascites cells. *EXS*, **62**, 124–135.
- [62] D.P. Hartley, J.A. Ruth and D.R. Petersen (1995). The Hepatocellular Metabolism of 4-hydroxynonenal by alcohol dehydrogenase, aldehyde dehydrogenase, and glutathione S-transferase. *Archives of Biochemistry and Biophysics*, **316**, 197–205.
- [63] G. Barrera, S. Pizzimenti, G. Muzio, M. Maggiora, A. Garramone, F. Biasi, M.U. Dianzani and R.A. Canuto (1996). Enzymatic pattern of aldehyde metabolism during HL-60 cell differentiation. *Biochemical and Biophysical Research Communications*, **223**, 73–79.
- [64] J. Alary, F. Bravais, J.-P. Cravedi, L. Debrauwer, D. Rao and G. Bories (1995). Mercapturic acid conjugates as urinary end metabolites of the lipid peroxidation product 4-hydroxy-2-nonenal in the rat. *Chemical Research in Toxicology*, **8**, 34–39.
- [65] H. Esterbauer, H. Zollner and R.J. Schaur (1990). Aldehydes formed by lipid peroxidation: mechanisms of formation, occurrence and determination. In *Membrane Lipid Oxidation* (ed. C. Vigo-Pelfrey), Vol. I, CRC Press, Boca Raton, pp. 239–268.
- [66] H. Strohmaier, H. Hinghofer-Szalkay and R.J. Schaur (1995). Detection of 4-hydroxynonenal (HNE) as a physiological component in human plasma. *J. Lipid Mediators Cell Signalling*, **11**, 51–61.
- [67] M.A. Rossi, F. Fidale, C. Di Mauro, H. Esterbauer and M.U. Dianzani (1993). Effect of 4-hydroxy-2,3-trans-nonenal and related aldehydes on phospholipase C activity of rat neutrophils. *International Journal of Tissue Reactions*, **XV**, 201–205.
- [68] M.A. Rossi, C. Di Mauro, H. Esterbauer, F. Fidale and M.U. Dianzani (1994). Activation of phosphoinositide-specific phospholipase C of rat neutrophils by the chemotactic aldehydes 4-hydroxy-2,3-trans-nonenal and 4-hydroxy-2,3-trans-octenal. *Cell Biochemistry and Function*, **12**, 275–280.
- [69] N. Zarkovic, Z. Ilic, M. Jurin, R.J. Schaur, H. Puhl and H. Esterbauer (1993). Stimulation of HeLa cell growth by physiological concentrations of 4-hydroxynonenal. *Cell Biochemistry and Function*, **11**, 279–286.
- [70] N.-G. He, S.S. Singhal, S.K. Srivastava, P. Zimniak, Y.C. Awasthi and S. Awasthi (1996). Transfection of a 4-hydroxynonenal metabolized glutathione S-transferase isozyme, Mouse GSTA4-4, confers doxorubicin resistance to Chinese hamster ovary cells. *Archives of Biochemistry and Biophysics*, **333**, 214–220.